journal
https://read.qxmd.com/read/38710379/rationale-and-design-of-a-single-center-randomized-trial-to-compare-the-graft-patency-between-the-radial-artery-and-the-no-touch-saphenous-vein-in-coronary-artery-bypass-grafting-surgery-graft-cab-study
#21
JOURNAL ARTICLE
Fengqing Zhang, Meice Tian, Xiaohu Wang, Haotian Zhang, Xingtong Zhou, Rui Liu, Rui Liu, Zejian Jin, Changwei Zhang, Xianqiang Wang
BACKGROUND: Previous studies suggested only the radial artery and the No-touch (NT) technique were effective in reducing graft occlusion after coronary artery bypass grafting (CABG) surgery. However, there is no randomized trial comparing these two graft conduits. The optimum second conduit for CABG remains undetermined. MATERIALS AND METHODS: This study is a prospective, single-center randomized clinical trial, aiming to compare the graft patency between the radial artery and the NT vein graft...
May 4, 2024: American Heart Journal
https://read.qxmd.com/read/38710378/low-density-lipoprotein-cholesterol-response-to-statins-according-to-comorbidities-and-co-medications-a-population-based-study
#22
JOURNAL ARTICLE
Giulia Corn, Marie Lund, Niklas W Andersson, Tine L Dohlmann, Mark A Hlatky, Jan Wohlfahrt, Mads Melbye
BACKGROUND: The response of low-density lipoprotein cholesterol (LDL-C) to statin therapy is variable, and may be affected by the presence of co-morbid conditions or the use of concomitant medications. Systematic variation in the response to statins based on these factors could affect the selection of the statin treatment regimen in population subgroups. We investigated whether common comorbidities and co-medications had clinically important effects on statin responses in individual patients...
May 4, 2024: American Heart Journal
https://read.qxmd.com/read/38705341/obicetrapib-on-top-of-maximally-tolerated-lipid-modifying-therapies-in-participants-with-or-at-high-risk-for-atherosclerotic-cardiovascular-disease-rationale-and-designs-of-broadway-and-brooklyn
#23
JOURNAL ARTICLE
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, John J P Kastelein, Christie M Ballantyne, Kausik K Ray, Ann Marie Navar, Steven E Nissen, Anne C Golberg, Liam R Brunham, Danielle Curcio, Erin Wuerdeman, Annie Neild, Douglas Kling, Andrew Hsieh, Mary R Dicklin, Brian A Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L Catapano, Michael H Davidson
Obicetrapib, a novel, selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), LDL particles, apolipoprotein (Apo) B, and lipoprotein(a) [Lp(a)] and increases high-density lipoprotein cholesterol (HDL-C) when added to statins with or without ezetimibe. By substantially reducing LDL-C, obicetrapib has the potential to lower atherogenic lipoproteins in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) whose LDL-C levels remain high despite treatment with available maximally tolerated lipid-modifying therapies, addressing an unmet medical need in a patient population at high risk for cardiovascular events...
May 3, 2024: American Heart Journal
https://read.qxmd.com/read/38701962/lifting-the-veil-off-treatment-effect-heterogeneity
#24
JOURNAL ARTICLE
Herbert I Weisberg, Megan Dailey Higgs
Clinicians often suspect that a treatment effect can vary across individuals. However, they usually lack "evidence-based" guidance regarding potential heterogeneity of treatment effects (HTE). Potentially actionable HTE is rarely discovered in clinical trials and is widely believed (or rationalized) by researchers to be rare. Conventional statistical methods to test for possible HTE are extremely conservative and tend to reinforce this belief. In truth, though, there is no realistic way to know whether a common, or average, effect estimated from a clinical trial is relevant for all, or even most, patients...
May 1, 2024: American Heart Journal
https://read.qxmd.com/read/38701961/comparison-of-down-sizing-strategy-hangzhou-solution-and-standard-annulus-sizing-strategy-in-type-0-bicuspid-aortic-stenosis-patients-undergoing-transcatheter-aortic-valve-replacement-rationale-and-design-of-a-randomized-clinical-trial
#25
JOURNAL ARTICLE
Yuchao Guo, Xianbao Liu, Ranxi Li, Stella Ng, Qiong Liu, Lihan Wang, Po Hu, Kaida Ren, Jubo Jiang, Jiaqi Fan, Yuxin He, Qifeng Zhu, Xinping Lin, Huajun Li, Jian'an Wang
BACKGROUND: There has not been a consensus on the prothesis sizing strategy in type 0 bicuspid aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR). Modifications to standard annular sizing strategies might be required due to the distinct anatomical characteristics. We have devised a Down Sizing Strategy for TAVR using a self-expanding valve specifically for patients with type 0 bicuspid AS. The primary aim of this study is to compare the safety and efficacy of Down Sizing Strategy with the Standard Annulus Sizing Strategy in TAVR for patients with type 0 bicuspid AS...
May 1, 2024: American Heart Journal
https://read.qxmd.com/read/38685464/computerized-clinical-decision-support-to-improve-stroke-prevention-therapy-in-primary-care-management-of-atrial-fibrillation-a-cluster-randomized-trial
#26
JOURNAL ARTICLE
Jafna Cox, Laura Hamilton, Lehana Thabane, Gary Foster, James MacKillop, Feng Xie, Antonio Ciaccia, Shurjeel Choudhri, Joanna Nemis-White, Ratika Parkash
BACKGROUND: Despite guidelines supporting antithrombotic therapy use in atrial fibrillation (AF), under-prescribing persists. We assessed whether computerized clinical decision support (CDS) would enable guideline-based antithrombotic therapy for AF patients in primary care. METHODS: This cluster randomized trial of CDS versus usual care (UC) recruited participants from primary care practices across Nova Scotia, following them for 12 months. The CDS tool calculated bleeding and stroke risk scores and provided recommendations for using oral anticoagulants (OAC) per Canadian guidelines...
April 27, 2024: American Heart Journal
https://read.qxmd.com/read/38685463/association-between-atrial-fibrillation-and-heart-failure-patient-reported-outcomes-across-the-ejection-fraction-spectrum
#27
JOURNAL ARTICLE
Khaled Elkholey, Zain Ul Abideen Asad, Esraa Shehata, Irina Mustafina, Marat Fudim, Stavros Stavrakis
BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure (HF) and is associated with worse clinical outcomes. We evaluated the relationship between AF and longitudinal changes in health-related quality of life (HRQoL) measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) in both HF with preserved (HFpEF) and reduced ejection fraction (HFrEF). METHODS: This is a post-hoc analysis of the TOPCAT and HF-ACTION trials. The effect of AF on KCCQ overall summary scores (OSS), in both trials, was examined using a mixed effects regression model...
April 27, 2024: American Heart Journal
https://read.qxmd.com/read/38679190/pregnancy-in-women-with-congenital-heart-disease-new-insights-into-neonatal-risk-prediction
#28
JOURNAL ARTICLE
Nour Rahnama, Nour Ben Jemâa, Arthur Colson, Agnès Pasquet, Laura Houard de Castro, Frédéric Debiève, Sophie Pierard
BACKGROUND: Advances in managing adult congenital heart disease (ACHD) have led to an increased number of women with CHD reaching childbearing age. This demographic shift underscores the need for improved understanding and prediction of complications during pregnancy in this specific ACHD population. Despite progress in maternal cardiac risk assessment, the prediction of neonatal outcomes for ACHD pregnancies remains underdeveloped. Therefore, the aims of this study are (1) to assess neonatal outcomes in a CHD women population, (2) to identify their predictive factors and (3) to propose a new risk score for predicting neonatal complications...
April 26, 2024: American Heart Journal
https://read.qxmd.com/read/38679189/two-randomized-controlled-trials-of-nudges-to-encourage-referrals-to-centralized-pharmacy-services-for-evidence-based-statin-initiation-in-high-risk-patients-rationale-and-design-of-the-super-lipid-program
#29
JOURNAL ARTICLE
Alexander C Fanaroff, Qian Huang, Kayla Clark, Laurie A Norton, Wendell E Kellum, Dwight Eichelberger, John C Wood, Zachary Bricker, Andrea G Dooley Wood, Greta Kemmer, Jennifer I Smith, Srinath Adusumalli, Mary Putt, Kevin G M Volpp
BACKGROUND: In patients with or at risk for atherosclerotic vascular disease, statins reduce the incidence of major adverse cardiovascular events, but the majority of U.S. adults with an indication for statin therapy are not prescribed statins at guideline-recommended intensity. Clinicians' limited time to address preventative care issues is cited as one factor contributing to gaps in statin prescribing. Centralized pharmacy services can fulfill a strategic role for population health management through outreach, education, and statin prescribing for patients at elevated ASCVD risk, but best practices for optimizing referrals of appropriate patients are unknown...
April 26, 2024: American Heart Journal
https://read.qxmd.com/read/38677504/association-of-patient-level-characteristics-with-long-term-outcomes-after-fontan-palliation-rationale-design-and-baseline-characteristics-of-the-pediatric-cardiac-care-consortium-fontan-cohort-study
#30
JOURNAL ARTICLE
Yanxu Yang, Tzu-Chun Chu, Divya Suthar, Asaad G Beshish, Matthew Oster, Alvaro Alonso, Yijian Huang, Gourav Modanwal, Lazaros Kochilas, Jessica H Knight
BACKGROUND: The Fontan operation is used to palliate single ventricle congenital heart defects (CHD) but poses significant morbidity and mortality risks. We present the design, planned analyses and rationale for a long-term Fontan cohort study aiming to examine the association of patient characteristics at the time of Fontan with post-Fontan morbidity and mortality. METHODS AND RESULTS: We used the Pediatric Cardiac Care Consortium (PCCC), a US-based, multicenter registry of pediatric cardiac surgeries to identify patients who underwent the Fontan procedure for single ventricle CHD between 1 and 21 years of age...
April 25, 2024: American Heart Journal
https://read.qxmd.com/read/38677503/the-effects-of-pregnancy-in-subjects-with-repaired-tetralogy-of-fallot
#31
JOURNAL ARTICLE
Valeria E Duarte, Kenichiro Yamamura, Katherine E Economy, Julia A Graf, Minmin Lu, Gabriele Egidy Assenza, Gauri R Karur, Anais Marenco, Ayako Ishikita, Madeline E Duncan, Tal Geva, Rachel M Wald, Anne Marie Valente
BACKGROUND: Previous reports reveal inconsistent findings of right ventricular (RV) changes following pregnancy in subjects with repaired tetralogy of Fallot (rTOF). METHODS: A two-center, retrospective cohort study which included women with rTOF who completed pregnancy that were matched to nulliparous women with rTOF by age at the time of baseline cardiac magnetic resonance (CMR), RV ejection fraction (RVEF), and indexed RV end-diastolic volume (RVEDVi). Pre-pregnancy and postpartum cardiac magnetic resonance (CMR) were analyzed and compared to sequential CMR of nulliparous subjects with rTOF...
April 25, 2024: American Heart Journal
https://read.qxmd.com/read/38649085/a-randomized-clinical-trial-of-catheter-ablation-and-antiarrhythmic-drug-therapy-for-suppression-of-ventricular-tachycardia-in-ischemic-cardiomyopathy-the-vanish2-trial
#32
JOURNAL ARTICLE
John L Sapp, Anthony S L Tang, Ratika Parkash, William G Stevenson, Jeff S Healey, George Wells
Recurrent ventricular tachycardia (VT) in patients with prior myocardial infarction is associated with adverse quality of life and clinical outcomes, despite the presence of implanted defibrillators (ICDs). Suppression of recurrent VT can be accomplished with antiarrhythmic drug therapy or catheter ablation. The Ventricular Tachycardia Antiarrhythmics or Ablation In Structural Heart Disease 2 (VANISH2) trial is designed to determine whether ablation is superior to antiarrhythmic drug therapy as first line therapy for patients with ischemic cardiomyopathy and VT...
April 20, 2024: American Heart Journal
https://read.qxmd.com/read/38670834/low-left-ventricular-outflow-tract-velocity-time-integral-predicts-normotensive-shock-in-patients-with-acute-pulmonary-embolism
#33
JOURNAL ARTICLE
Robert S Zhang, Eugene Yuriditsky, Ambika C Nayar, Lindsay Elbaum, Allison A Greco, Aaron J Rhee, Vikramjit Mukherjee, Norma Keller, Carlos L Alviar, James M Horowitz, Sripal Bangalore
In this study, we found that a low LVOT VTI (<15 cm), a simple bedside point-of-care measurement, predicts normotensive shock in patients with acute intermediate-risk PE.
April 17, 2024: American Heart Journal
https://read.qxmd.com/read/38621577/examining-lack-of-referrals-to-heart-valve-specialists-as-mechanisms-of-potential-underutilization-of-aortic-valve-replacement
#34
JOURNAL ARTICLE
Muhammad Etiwy, Laura D Flannery, Shawn X Li, Fritha J Morrison, Joonghee Kim, Varsha K Tanguturi, Chiara Fraccaro, Megan Coylewright, Alexander Turchin, Sammy Elmariah, Jason H Wasfy
BACKGROUND: Recent studies suggest that Aortic Valve Replacement (AVR) remains underutilized. AIMS: Investigate the potential role of non-referral to Heart Valve Specialists (HVS) on AVR utilization. METHODS: Patients with severe aortic stenosis (AS) between 2015 and 2018, who met class I indication for intervention, were identified. Baseline data and process-related parameters were collected to analyze referral predictors and evaluate outcomes...
April 13, 2024: American Heart Journal
https://read.qxmd.com/read/38621576/association-between-visit-frequency-continuity-of-care-and-pharmacy-fill-adherence-in-heart-failure-patients
#35
JOURNAL ARTICLE
Carine E Hamo, Amrita Mukhopadhyay, Xiyue Li, Yaguang Zheng, Ian M Kronish, Rumi Chunara, John Dodson, Samrachana Adhikari, Saul Blecker
BACKGROUND: Despite advances in medical therapy for heart failure with reduced ejection fraction (HFrEF), major gaps in medication adherence to guideline-directed medical therapies (GDMT) remain. Greater continuity of care may impact medication adherence and reduced hospitalizations. METHODS: We conducted a cross-sectional study of adults with a diagnosis of HF and EF≤40% with ≥2 outpatient encounters between 1/1/2017 and 10/1/2021, prescribed ≥1 of the following GDMT: 1) Beta Blocker, 2) Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker/Angiotensin Receptor Neprilysin Inhibitor, 3) Mineralocorticoid Receptor Antagonist, 4) Sodium Glucose Cotransporter-2 Inhibitor...
April 13, 2024: American Heart Journal
https://read.qxmd.com/read/38621575/baseline-characteristics-including-blood-and-urine-metal-levels-in-the-trial-to-assess-chelation-therapy-2-tact2
#36
JOURNAL ARTICLE
Ana Navas-Acien, Regina M Santella, Bonnie R Joubert, Zhen Huang, Yuliya Lokhnygina, Francisco Ujueta, Irina Gurvich, Nancy J LoIacono, Filippo Ravalli, Cynthia D Ward, Jeffery M Jarrett, Alfonsina De Leon Salazar, Robin Boineau, Teresa L Z Jones, Daniel B Mark, Jonathan D Newman, David M Nathan, Kevin J Anstrom, Gervasio A Lamas
BACKGROUND: The reduction in cardiovascular disease (CVD) events with edetate disodium (EDTA) in the Trial to Assess Chelation Therapy (TACT) suggested that chelation of toxic metals might provide novel opportunities to reduce CVD in patients with diabetes. Lead and cadmium are vasculotoxic metals chelated by EDTA. We present baseline characteristics for participants in TACT2, a randomized, double-masked, placebo-controlled trial designed as a replication of the TACT trial limited to patients with diabetes...
April 13, 2024: American Heart Journal
https://read.qxmd.com/read/38614235/-comparing-the-outcomes-of-rheumatic-heart-disease-in-pregnancy-complicated-with-and-without-atrial-fibrillation-a-propensity-score-matched-analysis
#37
JOURNAL ARTICLE
Anish Keepanasseril, Swaraj Nandini Pande, Yavana Suriya, Jyoti Baghel, Nivedita Mondal, Ajith Ananthakrishna Pillai, Santhosh Satheesh, Samuel C Siu
BACKGROUND: Atrial fibrillation (AF) may increase the risk of adverse maternal and fetal outcomes among pregnant with rheumatic valvular lesions (RHD). We aimed to assess the rate of occurrence of AF in pregnant with RHD and its impact on cardiac and maternal-fetal outcomes compared to those without it. METHODS: The study group consisted of pregnant women with RHD and AF (cases) and a matched comparison group of pregnant women with RHD but without AF (controls) was derived from the database of pregnant women with RHD receiving care at our center between 2011 and 2021...
April 11, 2024: American Heart Journal
https://read.qxmd.com/read/38614234/patient-characteristics-treatment-patterns-and-prognosis-in-drug-use-associated-infective-endocarditis-in-denmark-from-1999-2018
#38
JOURNAL ARTICLE
Jeppe Kofoed Petersen, Lucas Grove Vejlstrup Bager, Lauge Østergaard, Peter Laursen Graversen, Kasper Iversen, Henning Bundgaard, Lars Køber, Emil Loldrup Fosbøl
BACKGROUND: While the proportion of drug-use-associated infective endocarditis (DU-IE) has been increasing during the opioid crisis in the United States, it is unknown whether this is seen in Denmark, where several preventive means have been implemented. We aimed to assess the temporal proportion of DU-IE and examine the rate of IE recurrence and mortality. METHODS: This nationwide cohort study identified all patients with first-time infective endocarditis in 1999-2018...
April 11, 2024: American Heart Journal
https://read.qxmd.com/read/38608997/rationale-and-design-for-the-randomized-placebo-controlled-double-blind-trial-studying-the-effect-of-single-antiplatelet-therapy-clopidogrel-versus-dual-antiplatelet-therapy-clopidogrel-acetylsalicylic-acid-on-the-occurrence-of-atherothrombotic-events-following
#39
JOURNAL ARTICLE
Emilien C J Wegerif, Çağdaş Ünlü, Manon I Generaal, Rutger van den Bor, Peter M van de Ven, Michiel L Bots, Gert J de Borst
RATIONALE: Antiplatelet therapy (APT) is the standard of care after endovascular revascularization (EVR) in patients with peripheral artery disease (PAD). APT aims to prevent both major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Nonetheless, the rates of MACE and MALE after EVR remain high. In coronary artery and cerebrovascular disease, dual APT (DAPT)compared to acetylsalicylic acid alone has proven to reduce MACE without increasing the risk of major bleeding when applied for a restricted number of weeks...
April 10, 2024: American Heart Journal
https://read.qxmd.com/read/38582139/early-postpartum-blood-pressure-screening-is-associated-with-increased-detection-of-cardiovascular-risk-factors-in-women-with-hypertensive-disorders-of-pregnancy
#40
JOURNAL ARTICLE
Melissa A Daubert, Amanda Stebbins, Rachel Peragallo-Urrutia, Karen Chiswell, Matthew S Loop, Ceshae Harding, Thomas Price, Tracy Y Wang
BACKGROUND: Hypertensive disorders of pregnancy (HDP), including gestational hypertension, preeclampsia, and eclampsia, are risk factors for cardiovascular (CV) disease. Guidelines recommend that women with HDP be screened for the development of hypertension (HTN) within 6-12 months postpartum. However, the extent to which this early blood pressure (BP) screening is being performed and the impact on detection of CV risk factors is unknown. METHODS: Women with HDP and without pre-existing hypertension (HTN) who had at least 6 months of clinical follow-up were categorized by postpartum BP screening status: early BP screen (6-12 months after delivery) or late BP screen (≥12 months after delivery)...
April 4, 2024: American Heart Journal
journal
journal
23294
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.